Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences, Inc. filings document a clinical-stage biopharmaceutical issuer focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Its 8-K reports cover operating and financial results, Regulation FD clinical disclosures, material events, capital-structure matters and exhibits such as press releases and clinical presentations.
Proxy materials describe annual meeting matters, stockholder voting, board and compensation governance and equity incentive plan administration. The filing record also identifies Forte’s common stock, par value $0.001 per share, listed on Nasdaq under the symbol FBRX.
Forte Biosciences, Inc. Schedule 13G/A shows OrbiMed Advisors LLC beneficially owns 884,230 shares of common stock (4.3%) and OrbiMed Capital LLC beneficially owns 312,725 shares (1.5%). The reporting persons state they aggregate 5.8% of the class held on behalf of other persons and that investment and voting power is exercised through a management committee of Carl L. Gordon, Sven H. Borho, and W. Carter Neild.
The filing discloses voting and dispositive power split: OrbiMed Advisors reports shared voting and shared dispositive power over 884,230 shares; OrbiMed Capital reports sole voting and sole dispositive power over 312,725 shares. Signatures are dated 05/15/2026.
Forte Biosciences, Inc. Schedule 13G/A amendment shows that Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen reported 0% beneficial ownership of Forte Biosciences common stock as of the close of business on March 31, 2026. The filing lists the reporting persons' principal business address and CUSIP 34962G208.
Forte Biosciences, Inc. ownership filing: MPM BioImpact LLC reports beneficial ownership of 1,000,682 shares of common stock, representing 7.2% of the class as reported in the filing. The filing shows sole voting and dispositive power over these shares. The signature date is 05/15/2026.
Alger Associates, Inc. amended its Schedule 13G to report beneficial ownership of 1,272,596 shares of Forte Biosciences common stock, equal to 10.2% of the class. The filing states these shares are held in open-end investment companies and managed accounts of Fred Alger Management, LLC, a wholly owned subsidiary of Alger Group Holdings, LLC, which in turn is a subsidiary of Alger Associates, Inc. The filing lists sole voting power of 1,268,303 shares and sole dispositive power of 1,272,596 shares. Signature date is 05/15/2026.
Janus Henderson Group plc reports beneficial ownership of common stock in FORTE BIOSCIENCES, INC. The filing states the Asset Managers under Janus Henderson beneficially hold 1,387,178 shares of common stock, representing 9.99% of the class. The filing also lists 299,798 pre-funded warrants that cannot be exercised to the extent they would result in ownership over 9.99%. The disclosure describes investment and voting discretion exercised on behalf of managed client portfolios.
Forte Biosciences reported a larger first quarter 2026 net loss while advancing its lead drug candidate FB102. The company posted a net loss of $22.1 million, or $(1.24) per share, compared with a $15.7 million loss a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $20.5 million, largely from FB102 Phase 2 celiac disease and Phase 1b vitiligo and alopecia areata trials, while general and administrative costs declined to $2.0 million helped by a $2.3 million interim legal settlement payment from an insurance carrier.
The FDA granted FB102 Fast Track Designation in celiac disease, and Forte highlighted upcoming topline data for Phase 1b vitiligo and Phase 2 celiac disease studies. The company held $58.2 million in cash and cash equivalents at March 31, 2026 and subsequently raised $172.5 million in gross proceeds in an April equity offering, issuing 6.6 million additional common shares.
Affinity Asset Advisors, LLC and Michael Cho report beneficial ownership of 1,011,890 shares of Forte Biosciences common stock, representing approximately 7.3% of the outstanding shares as of March 31, 2026. The filing cites 13,885,668 shares outstanding as of March 27, 2026, per the issuer's Form 10-K.
The shares are held directly by Affinity Healthcare Fund, LP; Affinity Asset Advisors serves as the fund's investment manager and exercises sole voting and dispositive power over the reported shares. The amendment is signed by the reporting persons and dated May 14, 2026.
Forte Biosciences (Common Stock) Schedule 13G: Adage Capital Management and affiliated reporting persons disclose beneficial ownership of 950,000 shares of common stock, representing 6.84% of the class based on 13,885,668 shares outstanding as of March 27, 2026. The shares are directly held by Adage Capital Partners, L.P. and reported with shared voting and shared dispositive power by the named reporting persons.
The filing identifies the reporting persons, their business address, and the CUSIP 34962G208. Ownership percentages and the outstanding share base are taken from the company’s Annual Report on Form 10-K for the year ended December 31, 2025, as referenced in the statement.
Forte Biosciences, Inc. reported a net loss of $22.1 million for the three months ended March 31, 2026, wider than the prior-year period, as it ramped spending on its lead autoimmune antibody FB102.
Research and development expenses rose to $20.5 million, driven by a Phase 2 trial in celiac disease and Phase 1b trials in non-segmental vitiligo and alopecia areata, while general and administrative expenses declined to $2.0 million, helped by a $2.3 million interim insurance recovery related to litigation defense costs. Cash and cash equivalents were $58.2 million as of March 31, 2026, with operating cash outflows of $18.8 million in the quarter.
After quarter-end, Forte strengthened its balance sheet through an April 2026 equity offering generating $172.5 million in gross proceeds and $162.1 million in net proceeds before other offering expenses, and believes this funding, together with existing cash, will support operations for at least twelve months from the filing date while advancing FB102 through ongoing clinical trials.
Forte Biosciences, Inc. reported a net loss of $22.1 million for the three months ended March 31, 2026, wider than the prior-year period, as it ramped spending on its lead autoimmune antibody FB102.
Research and development expenses rose to $20.5 million, driven by a Phase 2 trial in celiac disease and Phase 1b trials in non-segmental vitiligo and alopecia areata, while general and administrative expenses declined to $2.0 million, helped by a $2.3 million interim insurance recovery related to litigation defense costs. Cash and cash equivalents were $58.2 million as of March 31, 2026, with operating cash outflows of $18.8 million in the quarter.
After quarter-end, Forte strengthened its balance sheet through an April 2026 equity offering generating $172.5 million in gross proceeds and $162.1 million in net proceeds before other offering expenses, and believes this funding, together with existing cash, will support operations for at least twelve months from the filing date while advancing FB102 through ongoing clinical trials.